{"filing":{"accession_number":"0001178913-26-004136","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"zk2635972.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004136/zk2635972.htm"},"events":[{"id":27787,"run_id":25361,"accession_number":"0001178913-26-004136","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a classic earnings release disclosure under Item 2.02. The filing announces \"financial results for the second quarter and six months ended June 30, 2026\" with detailed financial metrics (R\u0026D expenses, G\u0026A expenses, net loss) and a press release attached as Exhibit 99.1. The disclosure includes both financial results and material business updates (Phase 2/3 clinical trial initiation, regulatory approvals, financing activities), making it material to investors assessing the company's progress and financial condition.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29463,"accession_number":"0001178913-26-004136","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The filing announces \"financial results for the second quarter and six months ended June 30, 2026\" with detailed financial metrics (R\u0026D expenses, G\u0026A expenses, net loss) and a press release attached as Exhibit 99.1. The disclosure includes both financial results and material business updates (Phase 2/3 clinical trial initiation, regulatory approvals, financing activities), making it material to investors assessing the company's progress and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T13:01:52.722448+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29463,"accession_number":"0001178913-26-004136","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a classic earnings release disclosure under Item 2.02. The filing announces \"financial results for the second quarter and six months ended June 30, 2026\" with detailed financial metrics (R\u0026D expenses, G\u0026A expenses, net loss) and a press release attached as Exhibit 99.1. The disclosure includes both financial results and material business updates (Phase 2/3 clinical trial initiation, regulatory approvals, financing activities), making it material to investors assessing the company's progress and financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T13:01:52.722448+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-08-14"}]}